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methods of managing low grade cervical cytological
abnormalities detected at routine screening.
Design Cost analysis within multicentre individually
randomised controlled trial.
Setting Grampian, Tayside, and Nottingham.
Participants 4201 women with low grade abnormalities.
Interventions Cytological surveillance or referral to
colposcopyforbiopsyandrecallifnecessaryorreferralto
colposcopy with immediate treatment based on
colposcopic appearance.
Main outcome measures Data on resource use collected
from participants throughout the duration of the trial
(36 months), enabling the estimation of both the direct
(health care) and indirect (time and travel) costs of
management. Quality of life assessed at recruitment and
at 12, 18, 24, and 30 months, using the EQ-5D
instrument. Economic outcomes expressed as costs per
case of cervical intraepithelial neoplasia (grade II or
worse) detected, by trial arm, as confirmed at exit, and
cost utility ratios (cost per quality adjusted life year
(QALY) gained) for the three pairwise comparisons of trial
arms.
Results The mean three year discounted costs of
surveillance, immediate treatment, and biopsy and recall
were £150.20 (€177, $249), £240.30 (€283, $415), and
£241.10 (€284, $4000), respectively, viewed from the
health service perspective. From the social perspective,
mean discounted costs were £204.40 (€241, $339),
£339.90 (€440, $563), and £327.50 (€386, $543),
respectively. Estimated at the means, the incremental
cost effectiveness ratios indicated that immediate
treatment was dominated by the other two management
methods, although it did offer the lowest cost per case of
cervical intraepithelial neoplasia detected and treated.
The pronounced skews in the distributions indicated that
probabilistic uncertainty analysis would offer more
meaningfulestimatesofcost effectiveness.The observed
differences in the cost effectiveness ratios between trial
arms were not significant.
Conclusion Judged withinthe time frame of the TOMBOLA
evaluation, there is no compelling economic reason to
favouranyonefollow-upmethodovereitheroftheothers.
Trial Registration ISRCTN 34841617.
INTRODUCTION
By enabling cervical intraepithelial neoplasia to be
detected and treated, mass population screening
using smear tests has contributed to reducing the inci-
dence of cervical cancer throughout the United
Kingdom.
12 Women with normal test results require
no clinical management, other than routine recall for
future screening, whereas those with high grade
abnormalities should be referred for colposcopy. The
optimalmanagementofthosewithlow gradeabnorm-
alities detected on screening (borderline nuclear
abnormalities or mild dyskaryosis), however, has
been the subject of debate.
3-6 Two alternatives have
been advocated—namely, cytological surveillance
(further smear tests at regular intervals) or immediate
referral forcolposcopicexamination.When low grade
abnormalities are viewed at colposcopy, some clini-
cians favour a policy of “see and treat,” whereby
immediate excision, if indicated, is carried out in a sin-
gle visit. Others prefer a more conservative approach,
whereby one or more biopsies are taken at the initial
colposcopy, with women returning for treatment at a
later date as necessary.
Toinformthesemanagementdebates,arandomised
controlled trial (TOMBOLA, trial of management of
borderline and other low grade abnormal smears) was
establishedinthelate1990s.Thetrialisnowcomplete,
and full details of its rationale, design, and conduct are
available elsewhere.
7 We report on the economic eva-
luationconductedinparallelwiththeclinicaltrial.The
primary function of cervical screening is to identify
premalignant lesions and we therefore estimated the
expected cost of detecting and treating a case of cervi-
cal intraepithelial neoplasia gradeIIor worse, foreach
of the three methods under investigation. The use of
evaluationresultsinhealthpolicyformulationrequires
outcomestobeassessedwithacommonmetric,and,in
the UK, this metric is the quality adjusted life year
(QALY). We present incremental cost effectiveness
ratios for pairs of management options in terms of
costs per QALY gained.
METHODS
Resource use
Cervical screening in the UK is provided by the state
funded National Health Services (NHS) and is
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lecteddataonuseofresourcesatthelevelofindividual
participantsthroughoutthethreeyearobservationper-
iod (initial recruitment to exit). To facilitate cost dis-
counting, we recorded the specific timing of every
management event relative to the recruitment base-
line. The principal resource using events contributing
to NHS screening costs were smear tests and colpo-
scopy examinations. The nature of the management
methods, however, meant that the colposcopies them-
selves were often accompanied by additional, contem-
poraneous interventions—for example, further smear
tests, biopsies, large loop excisions of the transforma-
tion zone, or cold coagulation. Resource use due to
after effects of management during the weeks after
the first surveillance smear or the first colposcopy
appointment was captured in questionnaires returned
by a subsample of trial participants.
In addition to the costs of cervical screening and
treatment borne by the NHS, we calculated costs
borne by others. Firstly, the opportunity costs of the
actual time consumed during consultations and treat-
ments were borne by women privately, their employ-
ers, or society as a whole. Secondly, women incurred
directcostsoftraveltoappointmentsandsomeneeded
to finance a substitute carer for their dependants.
Thirdly, many women were accompanied to their
appointments, resulting in additional opportunity
costs and travel expenses for companions. The data
on resource use required to estimate the costs of time
and travel were obtained from a questionnaire survey
of a large subsample (n=2269) of participants.
8
Unit costs
The chosen evaluation baseline was 2004, the year in
or around which most of the resource use actually
occurred. Accordingly, all unit costs were translated
to 2004 prices using the hospital and community
health services pay and price index.
9
As routine smear taking in the UK has always been
organisedlocallyinprimarycare,theNHScostoftest-
ing varies across the countries. Accordingly, we took
the unit cost of a smear test to be the average of smear
test costs derived from three independent micro-cost-
ingstudies.Firstly,aspecificcostauditwasundertaken
in Nottingham. This study used data obtained from a
survey of resource use among local general practi-
tioners and cost records from the local cytology
laboratory.
10 The second study had collected data at
one of the Tayside centres before the start of the
trial.
11 The third had been conducted independently
aspartof the evaluation ofhuman papillomavirustest-
ing at pilot sites in Bristol, Norwich, and Newcastle.
12
The three independent estimates of the cost of a smear
test were, respectively, £24.30, £26.80, and £36.90 at
2004prices,yieldingameanunitcostof£29.30(€34.5,
$48.5 at current conversion rates).
The unit cost of colposcopy was derived from the
2003 NHS reference cost of outpatient colposcopy,
based on a national sample of about 250000 events.
13
The published reference cost included that of the
colposcopicexaminationitself,plusthecostsofbiopsy,
excision, or ablation if carried out. To identify the cost
oftheprocedurealone,weadjustedthepublishedaver-
age cost on the basis of the proportion of colposcopies
known to have been followed by each of these other
procedures in the English programme





The unit costs associated with the various procedures
related to colposcopy ranged from £111.40 for an
examinationonlyto£210.00foracombinedexamina-
tion, smear test, and large loop excision. A small num-
ber of smear tests and colposcopies occurred either
outside the trial areas or in private practice, although
these were all costed as for the corresponding proce-





cost per day and length of stay), or accident and
emergency.
17 A hospital outpatient attendance cost
£70.40, inpatient care cost £341.70 per day, and an
emergency admission cost £135.40. When the costs
of condition specific procedures performed were una-
vailable, we applied day reference costs for gynaecol-
ogypatients.All additionalprescribedmedicationwas
costed with British National Formulary (BNF) prices.
The questionnaire study
8 estimated time and travel
costs at £10.10 per attendance for a smear test and
£30.00 per attendance for colposcopy. Time costs
were calculated by combining the reported duration
of an event with the prevailing average wage.
18 Using
these estimates, we estimated the costs of time and tra-
vel for all formal contacts with care providers for each
participant. The estimate for attending a colposcopy
appointment without treatment was applied also to
investigations in the private sector and to hospital pro-
cedures, as a measure of entailed cost. In all cases, we
adjusted the time costs applied by the length of visit.
Absences from work due to complications and after
effects were costed at the prevailing average wage.
Reported contacts with specific health services (gen-
eral practitioner, nurse, NHS or trial help lines) were
costed according to the type of service consulted and
the mode ofcontact, eitherby telephone or in person.
9
These were apportioned as costs borne by the NHS or
the participant, as appropriate.
Outcomes
Although changes in health state utilities that arise as a
result of cervical screening have been modelled,
19 we
collected health state utility data in real time. Partici-
pants were invited to complete the EQ-5D
20 immedi-
ately before initial randomisation and at intervals
throughout the trial, specifically at 12, 18, 24, and
30 months after recruitment. In addition, a subsample
of women completed an EQ-5D questionnaire six
weeks after their first surveillance smear test or colpo-
scopy appointment. Using the established algorithms
for the UK,
2122 we translated EQ-5D classifications
directly into index scores. We were therefore able to
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theareaunderthecurverepresentingthetotalnumber
of QALYs experienced by the participant between
recruitment and 30 months thereafter. By implication,
the maximum outcome within the trial for each parti-
cipant was 2.5 undiscounted QALYs.
WedidnotexpectallwomentocompleteallEQ-5D
questionnaires,andmanywomenfailedtocompleteat
least one. We excluded from the analysis any woman
whose initial or final questionnaire was uncompleted
andalsoanywhosequestionnairesattwoormoreadja-
cent time points were missing. When a single utility
value was missing within the individual’s EQ-5D
sequence, we used linear interpolation between the
two known values on either side.
Cost effectiveness
The accounting conventions for economic evaluation
differ between countries. In England, the National
Institute for Health and Clinical Excellence (NICE)
stipulates an NHS perspective for costs, a validated
generic measure of individual health outcomes, and
an annual discount rate of 3.5% for both costs and
outcomes.
23 In most other countries, evaluations
adoptasocialperspective,wherebycostsincurredout-
side the confines of formal health care are also
included.
2425 Debate continues over the rate at which
health outcomes should be discounted, including
whether they should be discounted at all.
26-28 Unlike
England, Scotland does not place a priori restraints
on accounting conventions.
29 Given different conven-
tions, we evaluated under different assumptions with
respect to perspective and discount rate, and we pre-
sent two sets of results. For the first, we followed the
NICE approach, including only NHS costs and dis-
counting both costs and benefits at 3.5% a year. For
the second, we adopted a social perspective on costs
(NHS costs plus costs of time and travel) with costs
discounted at 3.5%,but benefits undiscounted.
Inallcaseswerefertocervicalintraepithelialneopla-
sia grade II or higher. The mean costs of detectionand
managementforeacharmcomprisedthecostsofman-
agement of all women in the arm, divided by the num-
ber of cases detected at any point during follow-up.
Having ranked the comparators by increasing cost,
we estimated the incremental cost effectiveness ratios
(the ratios of the mean incremental costs to the mean
incremental benefits) for the three pairwise compari-
sons. In view of the skew typical of trial data (positive
skewforcosts,negativeskewforoutcomes),arithmeti-
cally calculated means and confidence intervals are
generally misleading. We therefore fitted distributions
to the individual cost and outcome data for each arm
and thereafter used these to estimate the means and
distributions of the incremental cost effectiveness
ratios. We adopted the standard Monte Carlo
approach to uncertainty analysis,
30 using Palisade
@RISK version 4.5 with 10000 iterations for each
comparison.
Further details of the data collection and cost effec-
tiveness calculations are provided in the appendix on
bmj.com.
RESULTS
The economic evaluation sample comprised 4201
women, of whom 2219 had been randomised to cyto-
logicalsurveillance,982tocolposcopywithimmediate
treatment, and 1000 to colposcopy with biopsy and
recall. Table 1 shows the numbers and proportions
of women in each of the three trial arms receiving dif-
ferent numbers of smear tests and different types of
colposcopies. The category “colposcopies without
treatment” includes cases of colposcopic examination
only, or examination coupled with further smear tests
or with biopsies. For “colposcopies with treatment,”
the treatment concerned was large loop excision or
cold coagulation. Table 1 also shows the women in
each arm in whom cervical intraepithelial neoplasia
grade II or higher was detected before the exit colpos-
copies. Differences between the mean numbers of the
three different types of procedure by trial arm were
significant for all pairwise comparisons, with the






and recall χ2 P value
Participants receiving:
Smear tests:
≤2 451 (20.3) 564 (57.4) 524 (52.4) 662.5 <0.001
3-4 1302 (58.7) 390 (39.7) 437 (43.7) ——
>4 466 (21.0) 28 (2.9) 39 (3.9) ——
Colposcopies without treatment 307 (13.8) 670 (68.2) 994 (99.4) 2260.2 <0.001
Colposcopies with treatment 291 (13.1) 498 (50.7) 198 (19.8) 545.4 <0.001
Both types of colposcopy 207 (9.3) 188 (19.1) 193 (19.3) 85.2 <0.001
CIN grade II or higher 269 (12.1) 220 (22.4) 192 (19.2) 61.8 <0.001
Mean No received/participant:
Smear tests 3.39 2.30 2.40 ——
Colposcopies without treatment 0.24 0.75 1.21 ——
Colposcopies with treatment 0.13 0.55 0.21 ——
CIN=cervical intraepithelial neoplasia.
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by the women in the two colposcopy arms (one way
analysis of variance, with Bonferroni correction, at
5%). While each woman in the two colposcopy arms
underwent at least one colposcopy, most of those ran-
domised to surveillance (1824, 82.2%) were not sub-
jected to colposcopic investigation.
We had data on after effects from the intervention,
suchaspain,bleeding,ordischarge,from1646women
(53.9% from the surveillance arm). In the surveillance
arm1238women(55.8%)reportednoaftereffectswith
colposcopy compared with 667 (33.6%) in the colpo-
scopy arms (z=8.90, P<0.01); and 87 (3.9%) and 412
(20.8%) women, respectively, reported taking medica-
tion for after effects (z=10.51, P<0.01). Within the
whole trial sample, 82 women (2.0%) made a total of
96 visits to hospital as a result of their management.
These visits were a combination of 32 outpatient
appointments, 27 day case appointments, 17 inpatient
admissions,and20emergencyvisits,whichresultedin
six further admissions.
Table 2 presents average costs for the major cate-
gories of undiscounted costs, plus descriptive statistics
of total costs and outcomes, both undiscounted and
discounted at 3.5% a year. Of the three management
options,colposcopywithimmediatetreatmenthadthe
lowest cost for detection per case of cervical intra-
epithelial neoplasia. This result arose because the
higher costs per woman in comparison with surveil-
lance and, to a much lesser extent, with biopsy and
recall, were more than offset by the increased yield of
cervicalintraepithelialneoplasia(table 1).Theconsid-
erable skews of the distributions of cost and outcome
indicate the need for uncertainty analysis.
Table 3 presents the uncertainty analysis results for
the three pairwise comparisons. For each comparison,
the table shows the estimated mean incremental cost
effectiveness ratio, plus the likelihood of the nomi-
nated management option generating higher costs,
higherbenefits,oracceptablecosteffectivenessinrela-
tion to its nominated comparator. An “acceptable
incremental cost effectiveness ratio” is a cost per
QALY gained of up to and including £30000




In this study of management of low grade cervical
abnormalities our results indicate that different
approaches to follow-up had different cost and out-
come implications. Of the three approaches, cytologi-
cal surveillance was the cheapest, colposcopy with
biopsyandrecallwasassociatedwiththemostaverage
QALYs per person, and immediate treatment offered
thelowestcostspercaseofcervicalintraepithelialneo-
plasiadetected.Thesizeoftheconfidenceintervalsfor
the cost and outcome distributions, however, indicate
thatnoneofthethreeapproachescouldbeshowntobe
significantly more cost effective than the other two.
Thus, our economic evaluation of managing women
with low grade abnormalities detected at screening
has provided no scientific basis for choosing immedi-
ate referral to colposcopy in preference to continued
cytological surveillance, or vice versa.
Comparison with other studies
A recent review observed that immediate treatment
after an abnormal smear result has become “accepted
internationally.” The authors claimed that immediate
treatment “decreased patient anxiety” and offered
“low costs.”
32 Moreover, it has been taken torepresent
a “safer option” than surveillance in the current medi-
colegal climate.
33 Our results suggest that the higher
costs of immediate treatment were more than out-
weighed by its higher yield of neoplasia, making it a
lower cost method of detection of cervical intra-
epithelial neoplasia than cytological surveillance.
This finding echoes earlier predictions both from
models
3435 and from a previous empirical study,
36
although some researchers have found exactly the
opposite.
37
Nevertheless, the cost argument might be less clear
cutthanhaspreviouslybeenthought.Differentstudies
can have different protocols in terms of, for example,
thenumberofsmeartestsbeforereferraltocolposcopy
and the nature and extent of follow-up after colpo-
scopy. Different protocols imply different resource







Mean cost (£) by expenditure category:
Smear tests 101.9 68.7 71.5
Colposcopy without treatment 30.7 87.7 149.5
Colposcopy with treatment 25.1 106.3 40.7
Hospital visits 7.3 6.8 8.5
Complications 1.5 2.5 2.5
Time and travel (non-NHS) 59.1 107.1 94.2
NHS costs (£):
Mean 166.5 272.1 272.4
Median 89.5 231.4 220.7
IQR 89.5-148.2 172.7-313.5 172.6-319.5
Mean, discounted 150.2 240.3 241.1
Skew coefficient 2.80 3.64 2.88
Social costs (£):
Mean 225.6 379.1 366.6
Median 130.6 343.5 305.9
IQR 130.6-209.4 264.7-428.0 247.7-424.7
Mean, discounted 204.4 339.9 327.5
Skew coefficient 2.62 3.37 2.77
Outcomes (QALYs):
Mean 2.225 2.243 2.277
Median 2.348 2.348 2.383
IQR 2.120-2.500 2.120-2.500 2.165-2.500
Mean, discounted 2.129 2.149 2.181
Skew coefficient −2.83 −2.22 −2.92
Mean discounted costs (£) per CIN case detected:
NHS perspective 1241 1073 1256
Social perspective 1689 1517 1706
QALY=quality adjusted life year.
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The unit costs of the principal procedures depend on
accountingconventionsandarelikelytovarybetween
settings and between countries.
38 For example, were
the costs of smear tests to be lower relative to those of
excision, then the mean cost per case of cervical intra-
epithelial neoplasia with surveillance would be lower
relative to that with referral to colposcopy. In our
study, an £80 increase in the unit cost for colposcopy
withtreatmentwouldbesufficienttomakethecostper
case of cervical intraepithelial neoplasia with surveil-




Measuring outcomes as QALYs allowed us to
account for any consequences of management for
health state utility in terms of, for example, anxiety,
pain, or restrictions in activities over a period of 2.
5 years. Our results thus contrast with those of earlier
studies, which concerned themselves with health
impacts judged only within a short time frame of





ment of follow-up rather than of cancer prevention.
Judgments about long term cost effectiveness would
require modelling to be undertaken, although such
models would require information as yet unavailable.
By way of example, the exit colposcopies showed that
significantly more cases of cervical intraepithelial neo-
plasiawerereportedinthecolposcopyarmsthaninthe
surveillance arm. On the one hand, it is possible to
conclude that a higher level of detection of invasive
disease must eventually result from using surveillance
rather than colposcopic management. On the other, it
is conceivable that many such cases would regress.
4142
Women who did not might well be identified at future
routine screening attendances, entailing neither
adverse health consequences from non-detection at
present nor any additional costs. In fact, the higher
level of cervical intraepithelial neoplasia detected in
the colposcopy arms attests to the probability of over-
detection and overtreatment, although the extent of
this remains unclear. It has been shown that excision
might adversely affect future fertility and pregnancy
outcomes,
4344 implying the existence of further costs
of colposcopic management, as yet unaccounted for.
Policy implications
As the trial progressed, the UK screening programmes
began to replace conventional cytology with liquid
based cytology. A modelling exercise
45 had suggested
thatliquidbasedcytologywouldprovemorecosteffec-
tive than conventional cytology, and implementation
was guided by feasibility studies conducted at various
sites throughout the UK, including Scottish TOM-
BOLA centres. A proportion of women in our trial,
therefore, would have been screened with liquid based
cytology,althoughtheirresourceusewasevaluatedasif
they had undergone conventional cytology. From the
evaluationpointofview,itfollowsthatoursurveillance
arm does not represent current practice in the UK.
How the incremental cost effectiveness ratios of col-
poscopy relative to liquid based cytology surveillance,
asopposedtothatwithconventionalcytology,willdif-
fer from those estimated in the present analysis
depends on one’s interpretation of the current evi-




4647 and South Africa
48 have concluded that,
despite the additional cost, liquid based cytology
could offer test parameters (sensitivity and specificity)
inferior to those of conventional cytology. An Italian
trial has reported a fall in the positive predictive value
ofscreeningasaresultofusingliquidbasedcytology.
49
Meta-analysis of earlier research results has failed to
confirm the belief that liquid based cytology was asso-
ciated with a reduction in the rate of unsatisfactory
smear tests,
50 although recent case studies
5152 and
trials
49 have reported such a reduction. It therefore
remains unclear whether, on balance, liquid based
cytology does actually out perform conventional
cytology.
53 With respect to our trial, if the unit cost
and the false positive rate of liquid based cytology did
prove to be higher than that of conventional cytology,
the mean cost of management by surveillance would
increase, although the effect might possibly be amelio-
ratedbya reducedneedtorepeatunsatisfactorysmear
tests. Clearly, in the event of the surveillance method
becoming less efficient, the relative economic advan-
tage of the colposcopy options would increase corre-
spondingly.




Immediate treatment v surveillance:
Nominal ICER (£ per QALY) 4546 7378
Uncertainty analysis:
Higher costs (%) 81.0 83.7
Higher benefits (%) 51.9 52.1
Acceptable ICER (%) 51.1 50.5
95% CIs for ICER (£) −11 375 to 11 109 −22 977 to 23 262
Biopsy and recall v immediate treatment:
Nominal ICER (£ per QALY) 26 −370
Uncertainty analysis:
Higher costs (%) 47.9 44.1
Higher benefits (%) 53.9 56.2
Acceptable ICER (%) 53.4 55.4
95% CIs for ICER (£) −9390 to 9858 −18 698 to 21 344
Biopsy and recall v surveillance:
Nominal ICER (£ per QALY) 1764 2373
Uncertainty analysis:
Higher costs (%) 80.5 80.9
Higher benefits (%) 55.1 59.1
Acceptable ICER (%) 54.3 57.4
95% CIs for ICER (£) −12 989 to 11 196 −24 651 to 25 770
ICER=incremental cost effectiveness ratio; QALY=quality adjusted life year.
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